Indian Firms Gear Up for FY27 Demergers

The fiscal year 2027 is set for significant corporate restructuring as several major Indian companies plan to demerge their business units into separate, publicly traded entities. The main goals are to unlock shareholder value and improve operational efficiency. However, the process from announcement to realizing this value is challenging and requires strong execution and market acceptance.

Key Demerger Plans Unveiled

Companies are using demergers to simplify complex structures, which analysts believe can lead to clearer strategies and more accurate market valuations.

• Vedanta Limited plans to divide its operations into five separate listed companies, effective April 1, 2026, to simplify its large mining and metals business.
• Apollo Hospitals Enterprise Ltd is creating Apollo Healthtech Limited by merging its pharmacy and digital health operations, expected to finish by Q4FY27.
• Thomas Cook (India) Ltd will spin off its resorts business into Sterling Holiday Resorts Limited, aiming for completion in 15-18 months.
• Natco Pharma is separating its agrochemicals division into Natco Crop Health Sciences Ltd, with an appointed date of October 1, 2026.
• Religare Enterprises Ltd is splitting its insurance and financial services businesses into two distinct companies, targeting a Q1FY28 listing.

Execution Hurdles and Financial Pressures

The promise of unlocking value heavily depends on how well these demergers are executed.

Vedanta, facing a substantial debt of around $11 billion across its entities, must manage this across five new companies, even as it aims to reduce debt. Despite analyst optimism for growth, Vedanta's stock has traded flat since May 2024, suggesting market caution despite demerger news.

Apollo Hospitals has strong analyst backing with 'Buy' ratings, but faces questions about its high P/E ratio, trading above its competitors. Integrating digital health with its hospital network is a complex task.

Natco Pharma's agrochemical division, which made up only 1.48% of FY25 revenue, is being spun off into a competitive sector with giants like UPL Ltd. and PI Industries. This raises doubts about its immediate impact. Natco Pharma's P/E ratio of about 11x is much lower than the pharmaceutical industry average of 25.6x, indicating the market may not fully price in its potential.

For Vedanta, splitting into five entities with a debt-to-equity ratio of approximately 2.1190 presents a major challenge for refinancing and repaying debt, even with the demerger's goals. The management's past performance and the ability of new leadership teams to manage independent strategies will be crucial.

Natco Pharma's agrochemicals division faces intense competition from larger, established players, possibly limiting its growth. Past regulatory issues from the US FDA also add concerns about operational compliance.

Religare Enterprises' demerger announcement led to a 10% stock drop and a 'Strong Sell' rating from MarketsMojo. This shows investor doubt about the execution and financial viability of the separated businesses. The valuation of these new entities will be key, with risks of investors becoming too enthusiastic and pushing prices unsustainably high, especially for units like Apollo HealthCo, which is valued at ₹400 billion based on projected FY27 EBITDA and a 26x multiple.

Comparing Performance and Sector Outlooks

When compared to industry peers, the demerged companies face different market conditions.

Vedanta's P/E ratios, from 11.2x to 21.88x, are competitive against companies like Hindalco but lower than Tata Steel. The metals and mining sector, however, benefits from favorable economic trends.

Apollo Hospitals' P/E ratio of over 58x is a high premium. Its hospital segment is valued below peers like Narayana Health and Max Healthcare due to the pressure from its digital unit.

Thomas Cook (India)'s P/E of about 16.8x places it in a competitive hospitality sector where specialized companies are growing.

Religare Enterprises faces a tough challenge. Its demerger news was met with a stock decline and a 'Strong Sell' rating, highlighting investor skepticism about execution in the competitive financial services and insurance sectors.

Future Prospects for New Entities

While demergers aim to support focused growth and improve shareholder returns, success is a long-term prospect.

The market will closely watch the operational performance, debt management, and market position of the newly independent companies.

Analyst forecasts predict significant EBITDA and EPS growth for Vedanta and positive outlooks for Apollo HealthCo. However, these depend on successfully navigating execution challenges and changing market conditions.

For companies like Religare, overcoming investor doubt will be key.

The real test for these demerged businesses will be their ongoing ability to create value independently.